Core Viewpoint - Haizheng Pharmaceutical (600267) announced that its subsidiary, Zhejiang Haizheng Animal Health Products Co., Ltd., has received approval from the Ministry of Agriculture and Rural Affairs of the People's Republic of China for the new veterinary drug registration certificate for Nirocoxib Chewable Tablets, officially classified as a Class II new veterinary drug [1] Group 1 - The new veterinary drug, Nirocoxib Chewable Tablets, is intended for alleviating pain and inflammation caused by canine osteoarthritis and clinical surgeries [1] - The registration application for Nirocoxib Chewable Tablets was submitted in June 2022, and it was processed by the Ministry of Agriculture and Rural Affairs along with other entities [1] - The product is now ready for production and will be launched once it obtains the veterinary product approval number, but it is not expected to have a significant impact on the company's performance in the short term [1]